Immunotyping inflammatory arthritis: Blood and synovial fluid cellular and molecular biomarkers in immune-mediated inflammatory diseases

Immunotyping inflammatory arthritis: Blood and synovial fluid cellular and molecular biomarkers in immune-mediated inflammatory diseases - Immunotyping inflammatory arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47311

Enrollment

700

Registered

2013-06-20

Start date

2013-07-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis inflammatory systemic diseases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - patients with an immune-mediated disease (e.g. systemic lupus, rheumatoid arthritis, gout) - patients of at least 18 years old

Exclusion criteria

Exclusion criteria: - patients who are unable to give informed consent

Design outcomes

Primary

Measure	Time frame
is to identify immunological alterations in the PB and SF of patients with various forms of inflammatory arthritis and systemic inflammatory diseases and to correlate these alterations with diagnosis, disease stage, prognosis, and treatment response. We thereby aim to identify and validate novel biomarkers that can be used fro personalized medicine in IMIDs	—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results